AJMC March 26, 2021
How are researchers leveraging what is currently known about the pathogenesis and progression of Parkinson disease into the development of potential novel therapies, and what role should neurologists and patients play in addressing this neurodegenerative condition?
As the second-most common neurodegenerative condition worldwide, the prevalence of Parkinson disease (PD) is increasing at a faster rate than any other neurodegenerative disease, with cases expected to reach between 8.7 million and 9.3 million by 2030.
The current gold standard of treatment for PD, levodopa, works to replace the loss of dopaminergic cells, although it causes several potentially debilitating adverse effects, particularly dyskinesia. Moreover, levodopa is known to lose efficacy over time, leading to the recurrence of motor and nonmotor symptoms, known as...
Today's Sponsors
Today's Sponsor